The DOI matches its Crossref record; 53 of the 53 references it cites were found in a registry or an index.
Rationale for and design of the Idiopathic Pulmonary Fibrosis–PRospective Outcomes (IPF-PRO) registry
Open accessAbstract
Background: Idiopathic pulmonary fibrosis (IPF) is a chronic interstitial lung disease characterised by progressive loss of lung function. Its clinical course is variable but ultimately fatal. There is a need for a multicentre patient registry incorporating longitudinal clinical data and biological samples to improve understanding of the natural history of IPF and contemporary practice patterns. Methods/design: The Idiopathic Pulmonary Fibrosis–PRospective Outcomes (IPF-PRO) registry is a national IPF registry in the USA. This registry will enrol approximately 300 patients with newly diagnosed IPF over 2 years at approximately 14 tertiary pulmonary care sites. Participants will be followed for 3–5 years and will receive usual care, as defined by their physician. Clinical data from the year prior to diagnosis will be collected from medical record review on enrolment. Subsequently, data on diagnostic evaluations, pulmonary function tests, physical examinations, laboratory data and clinical events will be collected at routine clinical visits and via a call centre. Participants will complete patient-reported outcome questionnaires at enrolment and then at approximately 6-month intervals. Blood samples for cellular, genetic and transcriptomic analyses will be collected at the same intervals. Results: The first results from the IPF-PRO registry will be presented in 2015. Conclusions: The IPF-PRO registry will improve understanding of the natural history of IPF, its impact on patients and current practice in the diagnosis and care of patients with IPF. The registry will establish a repository of biological samples from a well-characterised patient population for future research. Clinical trial number: NCT01915511.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
WARE, J. E., KOSINSKI, M., & KELLER, S. D. (1996) · Medical Care · doi:10.1097/00005650-199603000-00003 · Cited by 17,392
Austin, P. C. (2011) · Multivariate Behavioral Research · doi:10.1080/00273171.2011.568786 · Cited by 12,242 · cited 1×
“Standard approaches to the analysis of observational data will be used.(38) 39 All data analyses will be performed by the DCRI.”
MethodCrossing the Quality Chasm: A New Health System for the 21st Century
Baker, A. (2001) · BMJ · doi:10.1136/bmj.323.7322.1192 · Cited by 10,736
Applied Regression Analysis and Other Multivariable Methods
Walker, E. (1989) · Technometrics · doi:10.1080/00401706.1989.10488486 · Cited by 8,538
Raghu, G., Collard, H. R., Egan, J. J., Martinez, F. J., Behr, J., Brown, K. K., Colby, T. V., Cordier, J.-F., Flaherty, K. R., Lasky, J. A., et al. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.2009-040gl · Cited by 7,186
EQ-SD: a measure of health status from the EuroQol Group
Rabin, R., & Charro, F. D. (2001) · Annals of Medicine · doi:10.3109/07853890109002087 · Cited by 5,613
Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis
Richeldi, L., du Bois, R. M., Raghu, G., Azuma, A., Brown, K. K., Costabel, U., Cottin, V., Flaherty, K. R., Hansell, D. M., Inoue, Y., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402584 · Cited by 4,654
A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.
King, T. E., Bradford, W. Z., Castro-Bernardini, S., Fagan, E. A., Glaspole, I., Glassberg, M. K., Gorina, E., Hopkins, P. M., Kardatzke, D., Lancaster, L., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402582 · Cited by 3,975 · cited 1×
“1 Positive phase III trial results have been announced for nintedanib 4 and pirfenidone, 5 and in 2014, both these therapies were approved for the treatment of IPF by the US Food and Drug Administration.”
BackgroundLeavitt, M. (2001) · PubMed · Cited by 1,872
Clinical course and prediction of survival in idiopathic pulmonary fibrosis
Ley, B., Collard, H. R., & King, T. E. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201006-0894ci · Cited by 1,765
Research works printed but not linked: 1
- Dimmock, 2013, The GAP Index predicts mortality in a statewide cohort of patients with idiopathic pulmonary fibrosis [abstract], Am J Respir Crit Care Med, 187, A6086
Cited by
The natural history of progressive fibrosing interstitial lung diseases
Kolb, M., & Vašáková, M. (2019) · Respiratory Research · doi:10.1186/s12931-019-1022-1 · Cited by 269
Interstitial Lung Disease in India. Results of a Prospective Registry
Singh, S., Collins, B. F., Sharma, B. B., Joshi, J. M., Talwar, D., Katiyar, S., Singh, N., Ho, L., Samaria, J. K., Bhattacharya, P., et al. (2017) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201607-1484oc · Cited by 267
Jo, H. E., Glaspole, I., Grainge, C., Goh, N., Hopkins, P. M. A., Moodley, Y., Reynolds, P. N., Chapman, S., Walters, E. H., Zappala, C., et al. (2017) · European Respiratory Journal · doi:10.1183/13993003.01592-2016 · Cited by 233
Behr, J., Prasse, A., Wirtz, H., Koschel, D., Pittrow, D., Held, M., Klotsche, J., Andreas, S., Claussen, M., Grohé, C., et al. (2020) · European Respiratory Journal · doi:10.1183/13993003.02279-2019 · Cited by 198
Demographics and survival of patients with idiopathic pulmonary fibrosis in the FinnishIPF registry
Kaunisto, J., Salomaa, E.-R. M., Hodgson, U., Kaarteenaho, R. L., Kankaanranta, H., Koli, K. M., Vahlberg, T. J., & Myllärniemi, M. (2019) · ERJ Open Research · doi:10.1183/23120541.00170-2018 · Cited by 121
Metadata
- Authors
- O'Brien, E. C., Durheim, M. T., Gamerman, V., Garfinkel, S., Anstrom, K. J., Palmer, S. M., & Conoscenti, C. S.
- Affiliations
- Duke University (US)
- Boehringer Ingelheim (United States) (US)
- Duke Clinical Research Institute (US)
- Corresponding author
- O'Brien, Emily C
- Venue
- BMJ Open Respiratory Research
- Publisher
- BMJ
- Published
- 2016-01
- Volume
- 3
- Issue
- 1
- Pages
- e000108
- ISSN
- 2052-4439 (ISSN-L)
- PMC
- PMC4716211
- OpenAlex
- W2270214041
- Cited by
- 75
- References
- 53
- Citations by year
- 2026: 3 · 2025: 6 · 2024: 11 · 2023: 8 · 2022: 8 · 2021: 3 · 2020: 21 · 2019: 9 · 2018: 2 · 2017: 2 · 2016: 2
- FWCI
- 4.47
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by-nc
- Locations
- BMJ Open Respiratory Research (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Funders
- Duke Clinical Research Institute
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Occupational and environmental lung diseases
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Chronic Obstructive Pulmonary Disease (COPD) Research
- Keywords
- idiopathic pulmonary fibrosis, patient registry, natural history (disease), interstitial lung disease, patient-reported outcomes, biological specimen, lung function, clinical practice patterns
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Rationale for and design of the Idiopathic Pulmonary Fibrosis–PRospective Outcomes (IPF-PRO) registry. https://app.cochat.ai/papers/10.1136/bmjresp-2015-000108
- The paper
- O'Brien, E. C., Durheim, M. T., Gamerman, V., Garfinkel, S., Anstrom, K. J., Palmer, S. M., & Conoscenti, C. S. (2016). Rationale for and design of the Idiopathic Pulmonary Fibrosis–PRospective Outcomes (IPF-PRO) registry. BMJ Open Respiratory Research. https://doi.org/10.1136/bmjresp-2015-000108
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
